A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Cannot have received: cevostamab or another agent with the same target

Prior treatment with cevostamab or another agent with the same target

Cannot have received: monoclonal antibody

Exception: except for the use of non-myeloma therapy

Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC as anti-cancer therapy within 4 weeks before first study treatment, except for the use of non-myeloma therapy

Cannot have received: systemic immunotherapeutic agents

Prior treatment with systemic immunotherapeutic agents, including but not limited to, cytokine therapy and anti-CTLA-4, anti-PD-1, and anti-PD-L1

Cannot have received: CAR-T cell therapy

Prior treatment with CAR-T cell therapy within 12 weeks before first cevostamab infusion

Cannot have received: radiotherapy

Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment

Cannot have received: chemotherapeutic agent

Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment

Cannot have received: anti-cancer agent

Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment

Cannot have received: autologous stem cell transplantation

Autologous stem cell transplantation (SCT) within 100 days prior to first study treatment

Cannot have received: allogeneic stem cell transplantation

Prior allogeneic SCT

Cannot have received: solid organ transplantation

Prior solid organ transplantation